Oleanolic acid compound as well as preparation method and application thereof

By developing an oleanolic acid compound and its preparation method, multiple challenges of Aβ, tau protein phosphorylation and neuroinflammatory response in Alzheimer's disease were solved, and the protection effect on PC12 cells was achieved, showing potential Anti-Alzheimer's drug potential.

CN119080863APending Publication Date: 2024-12-06YANBIAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411249333.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-06
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

In the treatment of Alzheimer's disease, the prior art is difficult to effectively target the abnormal formation and deposition of Aβ, the phosphorylation of tau protein, and the neuroinflammatory response, resulting in neuronal damage and death.

Method used

A oleanoate compound prepared by specific synthetic methods shows anti-Alzheimer's disease effect, able to protect PC12 cells in vitro and inhibit Aβ-induced cell damage. The preparation method of the compound includes the addition of sodium azide and zinc bromide to benzonitrile, followed by reaction with potassium carbonate and dibromethane, and finally combined with oleanolic acid to obtain the target compound by extraction and purification.

Benefits of technology

This compound is non-toxic to PC12 cells below 20 μM and shows a much stronger cell protective activity than the lead compound and the positive drug donepezil, and has important application value for anti-Alzheimer's drug.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119080863A_ABST
    Figure CN119080863A_ABST
Patent Text Reader

Abstract

The invention discloses an oleanolic acid compound as well as a preparation method and application thereof, the oleanolic acid compound is a novel compound with anti-Alzheimer's disease activity, the oleanolic acid compound is obtained by structural modification and optimization on the basis of a natural product oleanolic acid, the pharmacological activity of the oleanolic acid is improved, the physicochemical property of the oleanolic acid is improved, and the anti-Alzheimer's disease activity of the oleanolic acid is improved. The druggability is enhanced. The oleanolic acid compound and the preparation method and application thereof have the advantages that the preparation method is simple, conditions are mild, and reagents are cheap and easy to obtain, and in-vitro CCK8 experimental results show that the protection effect of the oleanolic acid compound on A beta-induced PC12 cell injury is better than that of a lead compound and a positive drug donepezil; and the compound has no toxicity to PC12 cells below 20 [mu] M, and has an application value in preparation of anti-Alzheimer's disease drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of oleanolic acid derivatives, and in particular to an oleanolic acid compound and a preparation method and application thereof. Background Art

[0002] Alzheimer's disease (AD), clinical symptoms of AD include progressive cognitive decline, memory deterioration and inability to perform daily activities.

[0003] AD is characterized by neurofibrillary tangles caused by Aβ deposition and hyperphosphorylation of tau. In AD, abnormal formation and deposition of Aβ damage neurons, and Aβ stimulation promotes AD by inducing tau protein phosphorylation, aggregation, and fibrillation. In addition, neuroinflammatory response has recently become an important factor in AD. Aβ stimulation can activate astrocytes, which then disrupt neuronal homeostasis and induce neurotoxic damage by exerting inflammatory effector functions. Eliminating astrocyte inflammatory response can reduce neuronal death. Therefore, while targeting Aβ and tau protein phosphorylation, intervention in neuroinflammation is also an important direction for the treatment of AD. Summary of the invention

[0004] To solve the above problems, the present invention provides an oleanolic acid compound and a preparation method and application thereof. The compound exhibits an in vitro anti-Alzheimer's disease effect and can be used in the preparation of anti-Alzheimer's disease drugs and pharmaceutical compositions containing the same.

[0005] To achieve the above object, the present invention provides an oleanolic acid compound, the structure of which is shown below:

[0006]

[0007] The molecular formula of B1 is: C 39 H 56 N4O3; molecular weight: 628.44.

[0008] A method for preparing the above-mentioned oleanolic acid compound comprises the following steps:

[0009] S1. Add a mixture of water and isopropanol to benzonitrile to dissolve it, then add sodium azide and zinc bromide in sequence, stir and react at 82° C. for 24 h, add water and filter after the reaction is complete to obtain a white solid, which is then dried;

[0010] S2. The white solid obtained in step S1 is dissolved in DMF, potassium carbonate and dibromoethane are added, and the mixture is reacted at 60° C. After the reaction is complete, the mixture is extracted, dried, filtered under reduced pressure, and purified to obtain an intermediate;

[0011] S3, dissolving oleanolic acid in DMF, adding the intermediate obtained in step S2 and potassium carbonate, and reacting at 60° C.; after the reaction is complete, extracting, drying, filtering under reduced pressure, and purifying to obtain the target compound B1.

[0012] Preferably, in step S1, the benzonitrile compound includes one of p-fluorobenzonitrile, p-chlorobenzonitrile, p-methoxybenzonitrile, p-methylbenzonitrile, 3,4-dimethoxybenzonitrile, p-bromobenzonitrile and 3,4-dichlorobenzonitrile.

[0013] Preferably, in step S1, benzonitrile: water: isopropanol = 1 mmol: 2-4 mL: 1 mL.

[0014] Preferably, in step S1, benzonitrile: sodium azide: zinc bromide = 1 mmol: 1.2 mmol: 1.2 mmol.

[0015] Preferably, in step S2, DMF: potassium carbonate: dibromoethane = 4 mL: 1.5 mmol: 1.5 mmol.

[0016] Preferably, in step S3, oleanolic acid:DMF=1mmol:4mL;

[0017] The mass ratio of oleanolic acid: intermediate: potassium carbonate is 1 mmol: 1.5 mmol: 6 mmol.

[0018] Preferably, the extraction is performed by extracting with ethyl acetate three times and then extracting with saturated brine once.

[0019] The oleanolic acid compound of the present invention and its preparation method and application have the following beneficial effects:

[0020] (1) A novel oleanolic acid compound and a preparation method thereof, which has the advantages of simple reaction, mild conditions and cheap and readily available reagents;

[0021] (2) CCK8 experiments found that the compound was non-toxic to PC12 cells below 20 μM, and exhibited cell protective activity against Aβ-induced PC12 cells that was much stronger than that of the lead compound and the positive drug donepezil, which has important application value in the preparation of anti-Alzheimer's disease drugs.

[0022] The technical solution of the present invention is further described in detail below through the accompanying drawings and embodiments. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 The effect of the compound B1 of the present invention on the survival rate of PC12 cells at a concentration of 2.5 μM to 20 μM;

[0024] Figure 2The compound B1 of the present invention has a neuroprotective effect in inhibiting Aβ-induced PC12 cell damage. DETAILED DESCRIPTION

[0025] In order to make the purpose, technical scheme and advantages disclosed in the embodiments of the present invention more clearly understood, the embodiments of the present invention are further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the embodiments of the present invention and are not intended to limit the embodiments of the present invention. Based on the embodiments in this application, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of this application.

[0026] Embodiment 1

[0027] A method for preparing an oleanolic acid compound comprises the following steps:

[0028] S1. Take benzonitrile (1 mmol) in a round-bottom flask, add a mixture of water and isopropanol (5 mL, water: isopropanol = 4:1) to dissolve, then add sodium azide (1.2 mmol) and zinc bromide (1.2 mmol) in sequence, and stir at 82°C for 24 hours. After the reaction is complete, add water and filter to obtain a white solid, which is then dried.

[0029] S2. The white solid was treated with DMF (4 mL) solvent, potassium carbonate (1.5 mmol) and dibromoethane (1.5 mmol) were added, and the reaction was carried out at 60°C. After the reaction was complete, it was extracted with ethyl acetate three times, extracted with saturated brine once, dried over anhydrous sodium sulfate, and the solvent was removed by filtration under reduced pressure. Purification was carried out by column chromatography to obtain an intermediate.

[0030] S3. Dissolve 1 mmol of oleanolic acid in 4 mL of DMF, add 1.5 mmol of the intermediate and 6 mmol of potassium carbonate, and react at 60°C. After the reaction is complete, extract with ethyl acetate three times, extract with saturated brine once, dry with anhydrous sodium sulfate, remove the solvent by filtration under reduced pressure, and finally purify with column chromatography to obtain the target compound B1, which is a white powder with a yield of 59%.

[0031] The obtained compound B1 was named:

[0032] 2-(5-phenyl-1H-tetrazol-1-yl)ethyl

[0033] (4aS,6aS,6bR,8aR,10S,12aR,12bR,14bS)-10-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4 ,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-octadecahydropicene-4a(2H)-carboxylate;

[0034] The structural formula of the obtained compound B1 is:

[0035]

[0036] The molecular formula of the obtained compound B1 is: 39 H 56 N4O3; molecular weight: 628.44.

[0037] The NMR data of B1 are as follows:

[0038] 1 H NMR(300MHz,Chloroform-d)δ5.18(s,1H),4.94(ddd,J=9.9Hz,6.5,3.5Hz,3H),4.72(dd,J1=7.8Hz,J2=4.0Hz,1H),4.58–4.44 (m,1H),3.19(d,J=5.0Hz,0H),2.77(d,J=9.9Hz,0H),2.01–1.86(m,1H),1.64–1.53(m,10H),1.34–1.19(m,12H),0.02(s,1H).

[0039] 13 C NMR(75MHz, CDCl3)δ177.28,165.40,143.28,130.39,128.91(2C),127.29, 126.88(2C),122.62,78.99,61.38,55.10,51.91,47.51,46.82,45.67,41.5 1,41.12,39.16,38.70,38.35,36.94,33.75,33.03,32.41,32.31,30.63,28.09,27.46,27.18,25.79,23.54,23.30,22.79,18.19,16.67,15.54,15.20.

[0040] ESI-HRMS calculation for C 39 H 56 N4O3Na([M+ Na] + ):651.4252; found 651.4250.

[0041] Embodiment 2

[0042] Tablet formulation for 1000 tablets, each containing 100 mg of active ingredient: Example 1 Preparation of compound B1 (100 g), hydroxypropyl methylcellulose (2 g), wheat starch (10 g), sucrose (100 g), and magnesium stearate (6 g).

[0043] Test Example 1

[0044] CCK8 assay to determine the cytotoxic effect of compound B1 on PC12 cells

[0045] Take 100 μL of the solution with a density of 1×10 4 A PC12 cell suspension of 100 μL / mL was inoculated in a 96-well plate, and 100 μL of culture medium was added to the edge wells for 24 hours. The culture medium was gently aspirated, and 100 μL of DMEM culture medium containing oleanolic acid derivative B1 at concentrations of 2.5 μM, 5 μM, 10 μM, and 20 μM was added to the experimental group, and an equal volume of DMEM culture medium was added to the blank group. The cells were continued to be cultured in a sterile incubator for 24 hours. After 24 hours, 10 μL of CCK-8 was added to each well under light-proof conditions, and then cultured for 1 hour. The absorbance value (A value) at 450 nm was detected using an enzyme reader to calculate the cell survival rate.

[0046] Cell survival rate (%) = (average A value of the experimental group) / (average A value of the blank group) × 100%.

[0047] The results are as follows Figure 1 As shown, it can be seen that below a concentration of 20 μM, the compound B1 of the present invention has no obvious toxicity to PC12 cells.

[0048] Test Example 2

[0049] CCK8 assay to determine the protective effect of compounds on PC12 cells

[0050] Take 100 μL of the solution with a density of 1×10 4PC12 cell suspension of 100 μL / mL was inoculated in a 96-well plate, and 100 μL of culture medium was added to the edge wells, and cultured in a sterile incubator for 24 hours. After 24 hours, the culture medium was gently aspirated, and 200 μL of DMEM culture medium was added to the blank group; 200 μL of DMEM culture medium with a concentration of 20 mM Aβ was added to the Aβ group; Aβ with a final concentration of 20 mM and a final concentration of 0.625 μM-10 μM of compound B1 or a final concentration of 10 μM of oleanolic acid or a final concentration of 10 μM of donepezil were slowly added to the experimental group, and culture was continued for 24 hours. After 24 hours, the absorbance value (A value) at 450 nm was detected using an ELISA reader.

[0051] Cell survival rate (%) = (average A value of the experimental group - average A value of the blank group) / (average A value of the Aβ group - average A value of the blank group) × 100%.

[0052] The results are shown in Table 1 and Figure 2 As shown:

[0053] Table 1 Effect of compound B1 on the survival rate of PC12 cells induced by Aβ (0.625 μM-10 μM)

[0054] Group Cell survival rate (%) blank 100±0 Aβ <![CDATA[73.59 ### ±1.08]]> B10.625μM <![CDATA[82.81 *** ±0.57]]> B11.25μM <![CDATA[85.55 *** ±0.34]]> B12.5μM <![CDATA[88.45 *** ±0.58]]> B15μM <![CDATA[93.75 *** ±0.17]]> B1 10 μM <![CDATA[97.29 *** ±0.98]]> Oleanolic acid 10 μM <![CDATA[82.32 ** ±1.18]]> Donepezil 10 μM <![CDATA[85.94 *** ±0.75]]>

[0055] The results are the mean ± SD of three experiments. ### P<0.001 was statistically significant compared with the Control group; *** P<0.001 was statistically significant compared with the Aβ group.

[0056] The results showed that B1 had a good neuroprotective effect at 0.625μM-10μM (P<0.001), and its effect was stronger than oleanolic acid and donepezil at 10μM.

[0057] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that they can still modify or replace the technical solution of the present invention with equivalents, and these modifications or equivalent replacements cannot cause the modified technical solution to deviate from the spirit and scope of the technical solution of the present invention.

Claims

1. An oleanolic acid compound, characterized in that: Its structure is as follows: The molecular formula of B1 is: C 39 H 56 N4O3; molecular weight: 628.

44.

2. A method for preparing oleanolic acid compounds according to claim 1, characterized in that: The steps include: S1. Add a mixture of water and isopropanol to benzonitrile or a benzonitrile compound to dissolve it, then add sodium azide and zinc bromide in sequence, stir and react at 82° C. for 24 hours, and after the reaction is complete, add water and filter to obtain a white solid, which is then dried; S2. The white solid obtained in step S1 is dissolved in DMF, potassium carbonate and dibromoethane are added, and the mixture is reacted at 60° C. After the reaction is complete, the mixture is extracted, dried, filtered under reduced pressure, and purified to obtain an intermediate; S3, dissolving oleanolic acid in DMF, adding the intermediate obtained in step S2 and potassium carbonate, and reacting at 60° C.; after the reaction is complete, extracting, drying, filtering under reduced pressure, and purifying to obtain the target compound B1.

3. The method for preparing an oleanolic acid compound according to claim 2, characterized in that: In step S1, the benzonitrile compound includes one of p-fluorobenzonitrile, p-chlorobenzonitrile, p-methoxybenzonitrile, p-methylbenzonitrile, 3,4-dimethoxybenzonitrile, p-bromobenzonitrile and 3,4-dichlorobenzonitrile.

4. The method for preparing an oleanolic acid compound according to claim 2, characterized in that: In step S1, benzonitrile: water: isopropanol = 1 mmol: 2-4 mL: 1 mL.

5. The method for preparing an oleanolic acid compound according to claim 2, characterized in that: In step S1, benzonitrile: sodium azide: zinc bromide = 1 mmol: 1.2 mmol: 1.2 mmol.

6. The method for preparing an oleanolic acid compound according to claim 2, characterized in that: In step S2, DMF:potassium carbonate:dibromoethane=4 mL:1.5 mmol:1.5 mmol.

7. The method for preparing an oleanolic acid compound according to claim 2, characterized in that: In step S3, oleanolic acid: DMF = 1 mmol: 4 mL; The mass ratio of oleanolic acid: intermediate: potassium carbonate is 1 mmol: 1.5 mmol: 6 mmol.

8. The method for preparing an oleanolic acid compound according to claim 2, characterized in that: The extraction was performed by using ethyl acetate three times and saturated brine once.

9. Use of the oleanolic acid compound according to claim 1 in the preparation of an anti-Alzheimer's disease drug.